Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGF166 in Severe-to-profound Hearing Loss
NCT02132130Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2014
- Primary completion
- Dec 2019
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 2, open-label trial of CGF166 in hearing loss (5 arms), sponsored by Novartis. Primary endpoints: Number of Participants With Adverse Events at Week 52, Pure Tone Audiometry in Treated Ear at Day 600 and 2 more. Started Jun 2014; status: completed.
02
Drugs
CGF166
03
Conditions
hearing loss
Beyond the preview
Go deeper on NCT02132130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02132130.